Treatment regimen for aggressive blood cancer

Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found that patients with these lymphomas had improved survival rates when treated with small molecule inhibitors as second-line therapy, followed by epigenetic modifiers as…